No Prescription |
 |
 | ||
|
Amlogard |
|
| ||
No Prescription » Prescription Drugs 1 » Amlogard Amlodipine is prescribed for angina a condition characterized by episodes of crushing chest pain that usually results from a lack of oxygen in the heart muscle due to clogged arteries. Amlodipine is also prescribed for high blood pressure. It is a type of medication called a calcium channel blocker. These drugs dilate blood vessels and slow the heart to reduce blood pressure and the pain of angina.Amlodipine is in a class of drugs called calcium channel blockers. Amlodipine relaxes (widens) the blood vessels (veins and arteries) making it easier for the heart to pump and reducing its workload.Amlodipine is used to treat hypertension (high blood pressure) and to treat angina (chest pain). Buy Amlogard and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Amlogard: Product Type: Prescription Drugs 1 Amlogard/Norvasc ( Generic Amlodipine ) Amlogard/Norvasc (Generic Amlodipine) Generic Amlodipine 10mg 100 Tabs 5mg Generic Amlodipine Amlogard/Norvasc
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
